By inhibiting PD-L1 palmitoylation using small-molecule inhibitors (such as 2-BP) or peptide-based approaches (CPP-S1), researchers successfully reduced PD-L1 expression and restored T-cell-mediated anti-tumor immunity, providing a strong theoretical foundation for the development of novel cancer immunotherapies, particularly as a complementary strategy to current antibody-based treatments. Here, CD274 is linked to cancer.